Theory Paper IIDrNB Cardiology – Theory Notes
CARDIAC AMYLOIDOSIS; CURRENT GUIDELINE RECOMMENDATIONS IN MANAGEMENT
IHEART FAILURE AND HEMODYNAMIC MANAGEMENT (THE “GDMT PARADOX” — ESC 2021/2023 & ACC 2023 CONSENSUS)
- Pathophysiological Basis (Fixed Stroke Volume & Autonomic Neuropathy): Amyloid fibril infiltration produces a thick-walled, small-cavity, severely restrictive left and right ventricle with a steep diastolic pressure-volume curve and a fixed, low stroke volume. Because stroke volume cannot increase, cardiac output is strictly heart-rate dependent (CO = Fixed SV x HR), while concomitant amyloid autonomic neuropathy impairs compensatory baroreceptor vasoconstriction.
- Cornerstone Volume Management (Class I): Judicious Loop Diuretics (preferring Torsemide or Bumetanide over Furosemide due to superior oral bioavailability in right-sided gut edema) combined with Mineralocorticoid Receptor Antagonists (Spironolactone or Eplerenone) (supported mainly by observational data) and SGLT2 Inhibitors (Dapagliflozin/Empagliflozin), while avoiding aggressive over-diuresis that drops preload and precipitates prerenal azotemia and hypotension.
- Standard HFrEF Neurohormonal Blockers That Are Poorly Tolerated or Contraindicated:
- Non-Dihydropyridine Calcium Channel Blockers (Verapamil, Diltiazem — Avoid): Bind avidly to extracellular amyloid fibrils, causing severe negative inotropy, high-grade AV block, and cardiogenic shock.
- Digoxin (Avoid / Use Only with Extreme Caution): Binds directly to extracellular amyloid fibrils, resulting in elevated myocardial tissue concentrations and fatal arrhythmias / conduction block even when serum digoxin levels are within the “normal” therapeutic range.
- Beta-Blockers: Poorly tolerated and generally deprescribed/avoided in restrictive cardiac amyloidosis because blunting compensatory sinus tachycardia immediately drops cardiac output and precipitates decompensated heart failure and syncope.
- ACE Inhibitors, ARBs, and ARNI: Frequently precipitate severe orthostatic hypotension by blocking compensatory angiotensin-II vasoconstriction in patients with autonomic dysfunction. (For disabling orthostatic hypotension, Midodrine, Droxidopa, or compression stockings are used.)
IIARRHYTHMIA AND THROMBOEMBOLISM MANAGEMENT
- Universal Anticoagulation in Atrial Fibrillation / Flutter Irrespective of CHA2DS2-VASc Score (Class I): Amyloid infiltration of the left and right atria causes severe atrial myopathy, loss of atrial mechanical contraction (“atrial electromechanical dissociation”), and left atrial appendage (LAA) stasis, resulting in a 20 to 30 percent prevalence of intracardiac thrombi. Therefore, lifelong Oral Anticoagulation (DOACs or Warfarin) is Class I mandatory in ANY patient with Cardiac Amyloidosis and clinical or subclinical Atrial Fibrillation/Flutter, regardless of a CHA2DS2-VASc score of 0 or 1.
- Mandatory Transesophageal Echocardiography (TEE) Before Cardioversion: Because LAA thrombus is found far more often in Cardiac Amyloidosis than in other AF patients, even after >=3 weeks of therapeutic oral anticoagulation, a pre-procedural TEE (or Cardiac CT) is mandatory before every electrical cardioversion or catheter ablation, regardless of anticoagulation duration.
- Rhythm Control: Restoring sinus rhythm improves symptoms in early disease; Amiodarone is the safest antiarrhythmic drug (and Catheter Ablation is increasingly effective when performed in NYHA Class I–II before advanced atrial dilation).
IIIDISEASE-MODIFYING THERAPIES FOR TRANSTHYRETIN (ATTR) CARDIAC AMYLOIDOSIS
- TTR Tetramer Stabilizers (Bind the Thyroxine-Binding Site to Prevent Tetramer Dissociation into Monomers):
- Tafamidis (Class I, Level B — ATTR-ACT Trial, NEJM 2018): In 441 patients with ATTRwt or ATTRv cardiomyopathy, oral Tafamidis (80 mg meglumine or 61 mg free acid once daily) reduced all-cause mortality by 30 percent (HR 0.70) and cardiovascular hospitalizations by 32 percent over 30 months, while slowing decline in 6MWD and KCCQ score (with survival curves diverging at 18 months; ESC 2023 Class I for NYHA I–II; ACC/AHA 2022 Class IIa for NYHA I–III).
- Acoramidis (AG10 — ATTRibute-CM Trial, NEJM 2024; FDA Approved Nov 2024): Next-generation, enthalpically driven TTR stabilizer mimicking the super-stabilizing protective TTR Thr119Met genetic variant (achieving >90% TTR stabilization). In ATTRibute-CM (n = 632), oral Acoramidis (800 mg twice daily) significantly won on the primary 4-step hierarchical endpoint (Win Ratio 1.8; p < 0.0001), reducing cardiovascular hospitalizations by 50 percent and composite all-cause mortality or CV hospitalization.
- Hepatic TTR mRNA Gene Silencers (RNA Interference [siRNA] & Antisense Oligonucleotides [ASO]):
- Vutrisiran (GalNAc-Conjugated siRNA — HELIOS-B Trial, NEJM 2024; FDA Approved March 2025 for ATTR-CM): Subcutaneous Vutrisiran (25 mg every 3 months) silences hepatic TTR mRNA (>80–85% TTR knockdown). In the landmark Phase III HELIOS-B Trial (n = 655 patients with ATTRwt or ATTRv cardiomyopathy, 40% of whom were on background Tafamidis), Vutrisiran significantly reduced the primary composite of all-cause mortality and recurrent cardiovascular events by 28 percent overall (HR 0.72; p = 0.01) and by 33 percent in the monotherapy population, while reducing all-cause mortality by 35 percent over 42 months and preserving 6MWD and KCCQ. (Mandatory Vitamin A Supplementation [2,500–3,000 IU/day] is required with all TTR silencers because TTR transports retinol-binding protein.)
- Patisiran (APOLLO-B Trial, NEJM 2023) and Eplontersen (NEURO-TTRansform / CARDIO-TTRansform): IV Patisiran (every 3 weeks) preserved 6MWD and KCCQ at 12 months in APOLLO-B (FDA approved for ATTRv polyneuropathy), while the monthly subcutaneous GalNAc-ASO Eplontersen (approved for ATTRv polyneuropathy) did not meet its primary endpoint of CV mortality and recurrent CV events in the Phase III CARDIO-TTRansform trial (n = 1,432; ESC 2026).
- Investigational Gene Editing and Amyloid Depletors:
- In-Vivo CRISPR-Cas9 Gene Editing (Nexiguran Ziclumeran / NTLA-2001 — MAGNITUDE Trial): A single intravenous lipid-nanoparticle infusion permanently knocks out the hepatic TTR gene, achieving a sustained ~90 percent reduction in serum TTR (the MAGNITUDE trial was placed on FDA clinical hold in October 2025 after severe liver laboratory abnormalities in a participant).
- Anti-ATTR Depleting Monoclonal Antibodies (Coramitug / PRX004, ALXN2220 / NI006): Target cryptic epitopes exposed only on misfolded ATTR fibrils to trigger macrophage-mediated antibody-dependent phagocytosis and clear existing myocardial deposits.
| Therapeutic Class & Agent | Molecular Mechanism & Route | Landmark Trial | Primary Clinical Outcome & Approval Status |
|---|---|---|---|
| Tafamidis (TTR Stabilizer) | Binds T4 pocket of TTR tetramer; oral 61 mg / 80 mg OD | ATTR-ACT (NEJM 2018) | 30% reduction in mortality, 32% reduction in CV hospitalizations; ESC Class I (NYHA I–II) |
| Acoramidis (TTR Stabilizer) | Mimics protective Thr119Met variant (>90% stabilization); oral 800 mg BD | ATTRibute-CM (NEJM 2024) | Win Ratio 1.8 (p <0.0001); 50% reduction in CV hospitalizations; FDA approved (2024) for ATTR-CM |
| Vutrisiran (TTR siRNA Silencer) | GalNAc-siRNA cleaves hepatic TTR mRNA; 25 mg SC every 3 months (+ Vitamin A) | HELIOS-B (NEJM 2024) | 28% reduction in death/CV events (35% mortality reduction at 42 mo); FDA approved (2025) for ATTR-CM & ATTRv-PN |
| Daratumumab + CyBorD (AL Amyloidosis) | Anti-CD38 mAb + Cyclophosphamide, Bortezomib, Dexamethasone | ANDROMEDA (NEJM 2021) | 53.3% vs. 18.1% complete hematologic response; doubled cardiac organ response; Class I for AL |
IVMANAGEMENT OF IMMUNOGLOBULIN LIGHT-CHAIN (AL) CARDIAC AMYLOIDOSIS
- Medical Oncology Emergency (Class I): Untreated AL cardiac amyloidosis (where circulating free light chains exert direct p38-MAPK cardiotoxic oxidative stress in addition to fibril infiltration) has a median survival of less than 6 months from heart failure onset.
- First-Line Standard of Care — Daratumumab-CyBorD (ANDROMEDA Trial, NEJM 2021): Subcutaneous Daratumumab (anti-CD38 plasma-cell monoclonal antibody) added to Bortezomib (proteasome inhibitor), Cyclophosphamide, and Dexamethasone tripled the complete hematologic response rate (53.3 percent vs. 18.1 percent), doubled 6-month cardiac organ response (41.5 percent vs. 22.2 percent, measured by >=30% and >=300 pg/mL drop in NT-proBNP), and improved major organ deterioration progression-free survival. (Monitor closely for bortezomib/dexamethasone fluid retention and cardiotoxicity.)
VCONDUCTION SYSTEM PACING, ICDs AND TRANSPLANTATION
- Permanent Pacing and CRT / Conduction System Pacing (Class I): High-grade AV block is common (especially after TAVR in dual aortic stenosis + ATTRwt); if significant right ventricular pacing burden (>20 to 40 percent) is anticipated, Cardiac Resynchronization Therapy (CRT) or Left Bundle Branch Area Pacing (LBBAP) is preferred over right ventricular apical pacing because dyssynchronous RV pacing acutely reduces stroke volume in a small restrictive LV.
- Restricted Role of Primary-Prevention ICDs: Routine primary-prevention ICD implantation based solely on LVEF <=35% is not generally recommended in advanced Cardiac Amyloidosis because sudden death in end-stage amyloidosis is frequently due to Electromechanical Dissociation (Pulseless Electrical Activity [PEA]) or complete heart block/asystole rather than shockable VT/VF; ICDs are Class I recommended for secondary prevention (sustained VT or resuscitated VF arrest with >1-year life expectancy).
- Orthotopic Heart Transplantation: Feasible in selected younger patients with isolated advanced ATTR-CM (combined with post-transplant TTR stabilizer/silencer therapy) or AL-CM (accompanied or followed by Autologous Stem Cell Transplantation [ASCT] / Dara-CyBorD to prevent recurrent graft amyloidosis).
Key references
- Maurer MS, Schwartz JH, Gundapaneni B, et al. (ATTR-ACT Study Investigators): Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy, New England Journal of Medicine, 2018.
- Gillmore JD, Judge DP, Cappelli F, et al. (ATTRibute-CM Investigators): Efficacy and Safety of Acoramidis in Transthyretin Amyloid Cardiomyopathy, New England Journal of Medicine, 2024.
- Fontana M, Berk JL, Gillmore JD, et al. (HELIOS-B Trial Investigators): Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy, New England Journal of Medicine, 2024.
- Kastritis E, Palladini G, Minnema MC, et al. (ANDROMEDA Trial Investigators): Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis, New England Journal of Medicine, 2021.
meritmedscript.comDr. Sidhartha Mullapudi
